In a phase 2 study in 153 heavily pretreated patients with advanced melanoma, lifileucel demonstrated an objective response rate (ORR) of 31.4%, median progression-free survival (PFS) of 4.1 months, and median overall survival of 13.9 months with a safety profile generally associated with known toxicities due to lymphodepleting chemotherapy and IL-2 (1). Here, IL2 is linked to melanoma.